Skip to content
Clinical Trials – home
CroatiaBack to Croatia

Clinical trials in Ivanic-Grad – page 10

259 clinical trials in Ivanic-Grad, Croatia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Ivanic-Grad at a glance
259
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

259 trials in Ivanic-Grad

Open in trial search

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:CroatiaCroatia
  • Participants:0–17 years
  • Sponsor:Amgen Inc.

Schizophrenia

Not recruiting

Study of evenamide as add-on treatment for patients with treatment-resistant schizophrenia not adequately controlled by current antipsychotic medications

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Evenamide
  • Sponsor:Newron Pharmaceuticals S.p.A.

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of SAR441566 for Adults with Moderate-to-Severe Ulcerative Colitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Balinatunfib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriatic arthropathy

Not recruiting

Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study on the Effects and Safety of Guselkumab for Patients with Active Psoriatic Arthritis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Ivanic-Grad

What the registry says about research in the country

01 Dermatology Research

Innovative clinical trials focusing on atopic dermatitis are evaluating new therapeutic approaches for both adolescents and adults with moderate to severe conditions. The research aims to assess novel treatment combinations and their effectiveness in managing eczema symptoms.

  • Moderate to Severe Atopic Dermatitis
  • Combination Therapy Studies
  • Systemic Treatment Options

Research includes evaluation of topical corticosteroid combinations and long-term treatment outcomes.

02 Inflammatory Skin Conditions

Studies are underway examining treatments for hidradenitis suppurativa, particularly focusing on patients who haven't responded well to conventional therapies. This research explores alternative treatment options for moderate to severe cases.

  • Treatment-Resistant Cases
  • Advanced Therapeutic Options
  • Anti-TNF Therapy Alternatives

The research specifically targets patients who have shown resistance to traditional treatments.

03 Advanced Therapeutics

Cutting-edge research investigating rezpegaldesleukin and other novel biologics for treating moderate-to-severe skin conditions. These trials are specifically designed for biologic-naive patients seeking new treatment options.

  • Biological Therapy Assessment
  • Dose Optimization Studies
  • Clinical Efficacy Evaluation

Focus includes measuring treatment effectiveness through standardized assessment tools.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.